Luye Pharma Group
Market Cap
HK$14.5b
Last Updated
2020/11/26 10:01 UTC
Data Sources
Company Financials +
Executive Summary
Luye Pharma Group Ltd. develops, produces, markets, and sells pharmaceutical products worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Undervalued with mediocre balance sheet.
Share Price & News
How has Luye Pharma Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2186 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 2186's weekly volatility (6%) has been stable over the past year.
Market Performance
7 Day Return
3.5%
2186
-0.4%
HK Pharmaceuticals
-0.5%
HK Market
1 Year Return
-27.5%
2186
3.0%
HK Pharmaceuticals
7.6%
HK Market
Return vs Industry: 2186 underperformed the Hong Kong Pharmaceuticals industry which returned 3% over the past year.
Return vs Market: 2186 underperformed the Hong Kong Market which returned 7.6% over the past year.
Shareholder returns
| 2186 | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.5% | -0.4% | -0.5% |
| 30 Day | -4.5% | -2.8% | 5.3% |
| 90 Day | 0% | -10.7% | 4.2% |
| 1 Year | -26.6%-27.5% | 4.7%3.0% | 11.9%7.6% |
| 3 Year | -9.7%-13.9% | -5.1%-10.6% | -1.2%-11.4% |
| 5 Year | -39.3%-43.5% | 30.7%20.3% | 29.7%7.9% |
Long-Term Price Volatility Vs. Market
How volatile is Luye Pharma Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Should You Be Excited About Luye Pharma Group Ltd.'s (HKG:2186) 17% Return On Equity?1 month ago | Simply Wall St
Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt4 months ago | Simply Wall St
Luye Pharma Group Ltd. (HKG:2186) Is Yielding 2.6% - But Is It A Buy?Valuation
Is Luye Pharma Group undervalued compared to its fair value and its price relative to the market?
41.6%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 2186 (HK$4.45) is trading below our estimate of fair value (HK$7.62)
Significantly Below Fair Value: 2186 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 2186 is good value based on its PE Ratio (9.5x) compared to the HK Pharmaceuticals industry average (10.7x).
PE vs Market: 2186 is good value based on its PE Ratio (9.5x) compared to the Hong Kong market (11.2x).
Price to Earnings Growth Ratio
PEG Ratio: 2186 is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: 2186 is overvalued based on its PB Ratio (1.6x) compared to the HK Pharmaceuticals industry average (1.1x).
Next Steps
Future Growth
How is Luye Pharma Group forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
11.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2186's forecast earnings growth (11.7% per year) is above the savings rate (1.6%).
Earnings vs Market: 2186's earnings (11.7% per year) are forecast to grow slower than the Hong Kong market (21.9% per year).
High Growth Earnings: 2186's earnings are forecast to grow, but not significantly.
Revenue vs Market: 2186's revenue (10.6% per year) is forecast to grow slower than the Hong Kong market (13.7% per year).
High Growth Revenue: 2186's revenue (10.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2186's Return on Equity is forecast to be low in 3 years time (13.8%).
Next Steps
Past Performance
How has Luye Pharma Group performed over the past 5 years?
15.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2186 has a high level of non-cash earnings.
Growing Profit Margin: 2186's current net profit margins (20.6%) are lower than last year (24.1%).
Past Earnings Growth Analysis
Earnings Trend: 2186's earnings have grown by 15.7% per year over the past 5 years.
Accelerating Growth: 2186's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2186 had negative earnings growth (-13.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-11.9%).
Return on Equity
High ROE: 2186's Return on Equity (17.1%) is considered low.
Next Steps
Financial Health
How is Luye Pharma Group's financial position?
Financial Position Analysis
Short Term Liabilities: 2186's short term assets (CN¥9.2B) exceed its short term liabilities (CN¥6.3B).
Long Term Liabilities: 2186's short term assets (CN¥9.2B) exceed its long term liabilities (CN¥5.4B).
Debt to Equity History and Analysis
Debt Level: 2186's debt to equity ratio (114.6%) is considered high.
Reducing Debt: 2186's debt to equity ratio has increased from 11.1% to 114.6% over the past 5 years.
Debt Coverage: 2186's debt is not well covered by operating cash flow (17.7%).
Interest Coverage: 2186's interest payments on its debt are well covered by EBIT (7.5x coverage).
Balance Sheet
Next Steps
Dividend
What is Luye Pharma Group current dividend yield, its reliability and sustainability?
2.17%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2186's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2186's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2186's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2186's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 2186 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2186's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
8.8yrs
Average management tenure
CEO
Dian Bo Liu (54 yo)
17.33yrs
Tenure
CN¥3,759,000
Compensation
Mr. Dian Bo Liu is a Co-Founder of Luye Pharma Group Ltd. in 1994 and serves as its Head of Corporate Directions & Strategies and has been its Chief Executive Officer since July 2003. Mr. Liu is responsibl...
CEO Compensation Analysis
Compensation vs Market: Dian Bo's total compensation ($USD571.67K) is about average for companies of similar size in the Hong Kong market ($USD562.86K).
Compensation vs Earnings: Dian Bo's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 17.33yrs | CN¥3.76m | no data | |
| Co-Founder & Vice Executive Chairman | 5.67yrs | CN¥2.71m | no data | |
| Co-Founder & Executive Director | 17.33yrs | CN¥1.35m | no data | |
| Executive Director | 6.67yrs | CN¥681.00k | no data | |
| Chief Financial Officer | 8.83yrs | no data | no data | |
| Senior VP & GM of Shandong Luye | no data | no data | no data | |
| Head of R&D and Senior VP | no data | no data | no data | |
| Head of International Business & VP | no data | no data | no data | |
| Company Secretary | 6.67yrs | no data | no data | |
| Chief Engineer of Shandong Luye Pharmaceutical Co Ltd | no data | no data | no data | |
| Assistant Company Secretary | no data | no data | no data |
8.8yrs
Average Tenure
54yo
Average Age
Experienced Management: 2186's management team is seasoned and experienced (8.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 17.33yrs | CN¥3.76m | no data | |
| Co-Founder & Vice Executive Chairman | 5.67yrs | CN¥2.71m | no data | |
| Co-Founder & Executive Director | 17.33yrs | CN¥1.35m | no data | |
| Executive Director | 6.67yrs | CN¥681.00k | no data | |
| Independent Non-Executive Director | 6.42yrs | CN¥432.00k | no data | |
| Independent Non-Executive Director | 6.42yrs | CN¥485.00k | no data | |
| Non-Executive Director | 3.67yrs | CN¥700.00k | no data | |
| Independent Non-Executive Director | 6.42yrs | CN¥432.00k | no data | |
| Independent Non-Executive Director | 6.42yrs | CN¥432.00k | no data |
6.4yrs
Average Tenure
58yo
Average Age
Experienced Board: 2186's board of directors are considered experienced (6.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Luye Pharma Group Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Luye Pharma Group Ltd.
- Ticker: 2186
- Exchange: SEHK
- Founded: 1994
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$14.523b
- Shares outstanding: 3.25b
- Website: https://www.luye.cn
Number of Employees
Location
- Luye Pharma Group Ltd.
- No. 15 Chuang Ye Road
- High-tech Industrial Development Zone
- Yantai
- Shandong Province
- 264003
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 2186 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Ordinary Shares | HK | HKD | Jul 2014 |
| LUP | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jul 2014 |
| 2186 | SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect) | Yes | Ordinary Shares | HK | HKD | Jul 2014 |
| 2186 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Yes | Ordinary Shares | HK | HKD | Jul 2014 |
Biography
Luye Pharma Group Ltd. develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and treatment for metastatic carcinoma of ovary; CMNa, a chemic...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/11/26 10:01 |
| End of Day Share Price | 2020/11/26 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.